For the Inventor, By the Inventor

Enter assignee name

Fort Washington, PA, United States of America

Rorer Pharmaceutical Corporation

USPTO Granted Patents = 109

Trademarks = 1

Forward Citations = 1,405

Loading Chart...

Loading Chart...

99 inventors (with patents filed for the assignee):

Henry F Campbell (45 out of 89 patents)

Donald E Kuhla (35 out of 59 patents)

William L Studt (31 out of 80 patents)

4. John T Suh (11 out of 49 patents)

5. Raymond D Youssefyeh (10 out of 27 patents)

6. William C Faith (9 out of 11 patents)

7. John R Regan (8 out of 51 patents)

8. Bruce F Molino (8 out of 22 patents)

9. Kent W Neuenschwander (8 out of 27 patents)

10. Robert A Galemmo, Jr (8 out of 27 patents)

11. Wayne M Grim (8 out of 10 patents)

12. Jerry W Skiles (7 out of 23 patents)

13. Stuart A Dodson (6 out of 25 patents)

14. Avinash M Contractor (6 out of 6 patents)

15. Alfred P Spada (5 out of 52 patents)

Core Competencies:

Anti-Thrombotic Peptides

HMG-CoA Reductase Inhibitors

Cardiotonic Compositions

Pharmaceutical Formulations

Quinoline Derivatives

Hypersensitivity Treatments

Calcitonin Analogues

Pharmacological Methods

Aryl Compounds

Bicyclic Ethers

Antiallergy Compounds

Peptic Ulcer Treatments

109 patents: Sort by Forward Citations

1. 5086069 - Anti-thrombotic peptide and pseudopeptide derivatives (1992-02-04),

2. 5026709 - Method for the preparation of a theophylline sustained release (1991-06-25),

3. 5002771 - Calcitonin suppository formulations (1991-03-26),

4. 4977246 - High recovery process for antihemophilic factor (1990-12-11),

5. 4977162 - Quinolinyl-chromone derivatives and use for treatment of hypersensitive (1990-12-11),

6. 4959485 - Hexahydrodibenzofuran carboxylic acid derivatives (1990-09-25),

7. 4954494 - Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in (1990-09-04),

8. 4952562 - Anti-thrombotic peptides and pseudopeptides (1990-08-28),

9. 4948582 - Treatment of conditions requiring enhanced oxygen availability to (1990-08-14),

10. 4946860 - Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors (1990-08-07),

11. 4944829 - Apparatus for applying wrappers (1990-07-31),

12. 4939143 - Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors (1990-07-03),

13. 4935511 - Benzoxazine and benzoxazepine carboxamide 5-HT.sub.3 antagonists (1990-06-19),

14. 4933445 - Heteroazabenzobicyclic carboxamide 5-HT.sub.3 antagonists (1990-06-12),

15. 4924010 - Benzoxepins as intermediates to 5HT.sub.3 antagonists (1990-05-08),

Company Overview

Rorer Pharmaceutical Corporation, based in Fort Washington, PA, specializes in the development and manufacturing of innovative pharmaceutical compounds. The company focuses on a diverse range of therapeutic areas, including anti-thrombotic peptides, HMG-CoA reductase inhibitors, and cardiotonic compositions. Rorer is dedicated to advancing healthcare through its expertise in pharmaceutical formulations and various pharmacological methods, addressing critical medical needs such as hypersensitivity treatments and calcitonin analogues.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

109 Patents

#3 in Fort Washington, PA

#137 in Pennsylvania

#3,503 in US

#7,220 in the World

Fort Washington, PA, United States of America

Rorer Pharmaceutical Corporation

Forward Citations = 1,405

99 inventors:

Henry F Campbell (45 out of 89 patents)

Donald E Kuhla (35 out of 59 patents)

William L Studt (31 out of 80 patents)

4. John T Suh (11 out of 49 patents)

5. Raymond D Youssefyeh (10 out of 27 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Rorer Pharmaceutical Corporation. Retrieved from https://idiyas.com/company/rorer-pharmaceutical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…